Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025Cephalalgia ReportsOpen Access

Long-term persistence of anti-calcitonin gene-related peptide monoclonal antibodies in treatment-resistant migraine: A three-year follow-up study in Spain

View Full Paper
Ask AI
Bookmark
Share

Authors

TGTania Garrido‐HernándezLZLuis Alberto Andrade ZumárragaPPPatricia Perea-Justicia

Discussion

Loading...

Member takes

Overview

Observational study reports adherence and outcomes of monoclonal antibodies in treatment-resistant chronic migraine at a tertiary hospital.

Key Points

  • This research assessed the long-term persistence of anti-CGRP monoclonal antibodies in patients resistant to migraine treatment.
  • Retrospective observational study conducted at a tertiary hospital.
  • Included adults with chronic or episodic migraine initiating therapy between February 2020 and May 2021.
  • Analyzed treatment persistence, switching, and discontinuation reasons using binary logistic regression.
  • After three years, 37% remained on their initial monoclonal antibody.
  • Total class-specific persistence rate was 66%, including patients who switched mAbs.
  • Discontinuation reasons included lack of efficacy (12%) and side effects (5%).

Cite This Study

Garrido‐Hernández et al. (2025) studied this question.

synapsesocial.com/papers/6925435ec0ce034ddc358065https://doi.org/10.1177/25158163251388920
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine2024 · 6 citations
  2. 2Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis2025 · 5 citations
  3. 3Reasons for discontinuation of CGRP antibody therapy: Insights from a retrospective real-world cohort study2026 · 1 citations
  4. 4Patient Adherence and Long-Term Tolerability of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention: A Systematic Review2025 · 2 citations
  5. 5Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data2025 · 1 citations